TY - JOUR T1 - EP351 Prevalence of genital infection by the human papilloma virus in the female population of gran canaria (Spain) JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - A243 LP - A243 DO - 10.1136/ijgc-2019-ESGO.410 VL - 29 IS - Suppl 4 AU - A Lubrano Rosales AU - A Torres Afonso AU - B Vega Guedes AU - M Andujar Sanchez Y1 - 2019/11/01 UR - http://ijgc.bmj.com/content/29/Suppl_4/A243.1.abstract N2 - Introduction/Background Cervical cancer is the fourth most commun female cancer worldwide after breast, colorectal and lung cancers. In Spain 1942 new cases were diagnosed during 2018, currently occupying the eleventh place among women of all ages. However, this cancer is the fourth in frequency among young women aged 25 to 44 years. Persistent infection with human papillomavirus (HPV) is considered a necessary cause for the development of a cervical carcinoma, and its distribution has been studied in many countries. The objectives of this study were to determine the prevalence of preneoplastic lesions of the cervix and the prevalence of HPV infection through molecular study in the female population of Gran Canaria.Methodology A cross-sectional population-based study was conducted among women between 18 and 65 years of age during the years 2004–2007. All the women after the signing of the informed consent were taken samples for cytology and HPV study. The sample size was 2,276 women.Results The average age was 41.56 years. 90.4% of cytologies were normal without evidence of intraepithelial lesion, 4.9% were classified as pathological: 3.4% ASCUS; 1.3% LSIL, 0.06% HSIL and 0.06% adenocarcinoma. High-risk HPV was positive in 12.56% (95% CI: 11–14%), 9.8% in negative cytology versus 42.8% in pathological cytology (P<0.001).Conclusion The prevalence of HPV in the female population of Gran Canaria was high, similar to previous studies published in Spain. These results support the benefit of routine HPV vaccination to control infection and prevent the burden of HPV-associated disease.Disclosure Nothing to disclose. ER -